Karen Noblett - 12 Sep 2022 Form 4 Insider Report for Axonics, Inc.

Role: Chief Medical Officer
Signature: /s/ Dan Dearen, as Attorney-in-Fact for Karen Noblett
Issuer symbol: N/A
Transactions as of: 12 Sep 2022
Net transactions value: -$1,915,465
Form type: 4
Filing time: 20 Sep 2022, 20:23:33 UTC
Previous filing: 09 Sep 2022
Next filing: 02 Feb 2023
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	AXNX	Common Stock	Options Exercise	$262,785	+18,519	+59%	$14.19^*	50,118	12 Sep 2022	Direct
transaction	AXNX	Common Stock	Options Exercise	$360,550	+13,964	+28%	$25.82	64,082	12 Sep 2022	Direct
transaction	AXNX	Common Stock	Sale	$2,538,800	-32,483	-51%	$78.16	31,599	12 Sep 2022	Direct	F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	AXNX	Stock Option (Right to Buy)	Options Exercise	$0	-18,519	-86%	$0.000000	2,963	12 Sep 2022	Common Stock	18,519	$14.19	Direct	F2
transaction	AXNX	Stock Options (Right to buy)	Options Exercise	$0	-13,964	-69%	$0.000000	6,348	12 Sep 2022	Common Stock	13,964	$25.82	Direct	F3

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	This transaction was executed in multiple trades at prices ranging from $78.00 to $78.47. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
F2	The option becomes exercisable as follows: (i) 1/4 of the total number of shares of common stock underlying the option will vest on January 30, 2020 and (ii) 1/36 of the remaining shares of common stock underlying the option will vest monthly thereafter, such that the option will fully vest on January 30, 2023, provided the reporting person remains in continuous service on each vesting date.
F3	The option becomes exercisable as follows: (i) 1/4 of the total number of shares of common stock underlying the option will vest on December 12, 2020 and (ii) 1/36 of the remaining shares of common stock underlying the option will vest monthly thereafter, such that the option will fully vest on December 1, 2023, provided the reporting person remains in continuous service on each vesting date.